Is GYRE THERAPEUTICS, INC. (GYRE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 3.6% / 30% | 3.9% / 30% | 1.46% / 5% | ✓ HALAL |
| DJIM | 0.2% / 33% | 3.6% / 33% | 3.9% / 33% | 1.46% / 5% | ✓ HALAL |
| MSCI | 1.3% / 33% | 21.3% / 33% | 23.2% / 33% | 1.46% / 5% | ✓ HALAL |
| S&P | 0.2% / 33% | 3.6% / 33% | 3.9% / 33% | 1.46% / 5% | ✓ HALAL |
| FTSE | 1.3% / 33% | 21.3% / 33% | 23.2% / 50% | 1.46% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 95.4% | |
| Operating Margin | 0.3% | |
| Net Margin | 4.3% | |
| Return on Equity (ROE) | 8.2% | |
| Return on Assets (ROA) | 4.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $1M |
| Free Cash Flow | -$913,000 |
| Total Debt | $939,000 |
| Debt-to-Equity | 0.7 |
| Current Ratio | 5.6 |
| Total Assets | $166M |
Price & Trading
| Last Close | $7.04 |
| 50-Day MA | $7.86 |
| 200-Day MA | $7.71 |
| Avg Volume | 97K |
| Beta | 6.9 |
|
52-Week Range
$6.11
| |
About GYRE THERAPEUTICS, INC. (GYRE)
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Purification Calculator
As a halal stock with 1.46% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is GYRE THERAPEUTICS, INC. (GYRE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), GYRE THERAPEUTICS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is GYRE THERAPEUTICS, INC.'s debt ratio?
GYRE THERAPEUTICS, INC.'s debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.3%.
Does GYRE THERAPEUTICS, INC. require dividend purification?
Yes, GYRE THERAPEUTICS, INC. has an impermissible income ratio of 1.46%, which means 1.46% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are GYRE THERAPEUTICS, INC.'s key financial metrics?
GYRE THERAPEUTICS, INC. has a market capitalization of $653M, trailing P/E ratio of 339.0, and revenue of $117M. The company maintains a gross margin of 95.4% and a net margin of 4.3%. Return on equity stands at 8.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.